Radiopharmaceuticals and contrast media

Structure confirmed. Purity = 98%. Will ship with Certificate of Analysis (CoA)

Cell Line Description CMT 64 was isolated from a primary alveogenic lung carcinoma tumour mass in C57BL/lcrf mouse, achieving stable morphology and growth rate in culture, similar to the growth rate and morphology in the primary tumour, and in lung

Cell Line Origin Mouse C57BL/1CRF rectum carcinoma Cell Line Description Derivative of CMT93. Cells grow in coherent clumps.

Device Configuration: Cartridge

CN COL 3UM L100 D2.1 EA

CN COL 3UM L150 D2.1 EA

Device Configuration: Cartridge Other Notes Directions for Use Organism Retention: Microorganism reduction Mode of Action: Filtration (nominal) Application: BioProcessing Intended Use: Efficient particle and microorganism reduction Instructions for

Device Configuration: Cartridge

A potent and competitive antagonist for AMPA/kainate receptors (K i = 0.6 - 2.

Application CNQX has been used: as an &#945-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate blocker to study its effects on cytoneme formation in pluripotent embryonic stem cells (pESCs) glutamate blocker to reduce the synaptic

Application CNQX has been used: as an &#945-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate blocker to study its effects on cytoneme formation in pluripotent embryonic stem cells (pESCs) glutamate blocker to reduce the synaptic

Application CNQX has been used: as an &#945-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate blocker to study its effects on cytoneme formation in pluripotent embryonic stem cells (pESCs) glutamate blocker to reduce the synaptic